New drug cocktail targets tough leukemia in patients with RUNX1 mutation
NCT ID NCT04874194
First seen Nov 03, 2025 · Last updated May 22, 2026 · Updated 20 times
Summary
This study tested a combination of two drugs, omacetaxine and venetoclax, in 24 adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that had returned or not responded to treatment. All participants had a specific genetic change called RUNX1. The goal was to find the best dose and see if the combination could control the disease. The study was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.